Adicet Bio Inc

NASDAQ ACET

Data sourced from

and

Daily

Download Data

Adicet Bio Inc Price to Book Ratio (P/B) on June 03, 2024: 0.46

Adicet Bio Inc Price to Book Ratio (P/B) is 0.46 on June 03, 2024, a 154.43% change year over year. The price to book ratio compares the market price per share of a company's stock to its book value per share. It is calculated by dividing the market capitalization by the shareholders' equity minus treasury stock, divided by the number of outstanding shares. This ratio provides insights into how the market values a company relative to its book value. A ratio above 1 indicates the market values the company more than its book value, suggesting positive market sentiment.

Adicet Bio Inc 52-week high Price to Book Ratio (P/B) is 1.42 on February 08, 2024, which is 211.57% above the current Price to Book Ratio (P/B).
Adicet Bio Inc 52-week low Price to Book Ratio (P/B) is -0.91 on June 07, 2023, which is -299.43% below the current Price to Book Ratio (P/B).
Adicet Bio Inc average Price to Book Ratio (P/B) for the last 52 weeks is 0.48.

NASDAQ: ACET

Adicet Bio Inc

CEO	Mr. Chen Schor BA, CPA, CPA, M.B.A., MBA
IPO Date	Jan. 26, 2018
Location	United States
Headquarters	200 Clarendon Street, Boston, MA, United States, 02116
Employees	143
Sector	Healthcare
Industry	Biotechnology

Description

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

Key trends